Skip to main content
Press Release

Adam Runsdorf and Woodfield Distribution, LLC, Agree to Pay $2.475 million to Resolve Allegations They Failed to Properly Account for Controlled Substances

For Immediate Release
U.S. Attorney's Office, Southern District of Florida

MIAMI – Adam Runsdorf and his companies, Florida-based drug wholesaler Woodfield Distribution, LLC and associated operations in Texas, surrendered their seven Drug Enforcement Administration (DEA) registrations and agreed to pay $2.475 million in civil fines to resolve violations of the Controlled Substances Act (CSA). These CSA requirements are designed to prevent the diversion of controlled substances.

Beginning in 2013 through 2016, Woodfield Distribution’s Florida location violated multiple CSA provisions, and as a result entered into a Memorandum of Agreement with the DEA to prevent future CSA violations. In 2018 and 2020, the DEA discovered additional CSA violations at Woodfield Distribution’s Florida and Texas locations. These CSA violations included: failure to account for over 120 million dosage units of controlled substances; failure to design and operate a system for monitoring suspicious orders; failure to notify the DEA of over 200,000 dosage units of stolen controlled substances; falsifying importation documents and the illegal importation of over 200 million dosage units of controlled substances; failure to properly store and secure controlled substances; lack of complete and accurate records; and failure to report controlled substance transactions and sales.

In August 2021, the DEA issued three Immediate Suspension Orders (ISO) for Woodfield Distribution’s Texas Distributor and Importer Registrations, as well as Manufacturer Registration for Woodfield Pharmaceuticals, LLC. The ISOs were issued for Woodfield’s failure to maintain effect controls and procedures against the theft and diversion of controlled substances and the imminent danger to public health and safety. ‘

In August 2022, a separate criminal investigation by DEA resulted in Adam Runsdorf and Woodfield Pharmaceuticals pleading guilty in the Eastern District of Texas to criminal charges of conspiracy, trafficking in counterfeit drugs, and money laundering conspiracy. According to the criminal indictment, from April 2014 until August 2021, Runsdorf, the owner and President of Woodfield Pharmaceutical based in Boca Raton, Florida, conspired with drug traffickers in Houston, Texas, to distribute misbranded and counterfeit cough syrup.

U.S. Attorney Markenzy Lapointe for the Southern District of Florida, U.S. Attorney Alamdar S. Hamdani for the Southern District of Texas, Special Agent in Charge Deanne L. Reuter of the DEA Miami Division, and Daniel Comeaux, Special Agent in Charge of the DEA Houston Division announced the resolution.

The DEA Miami Field Division, West Palm Beach District Office; DEA Houston Division Office, and DEA Galveston Resident Office investigated this matter. Assistant U.S. Attorney Mark Lavine from the Southern District of Florida and Assistant U.S. Attorney Jill Venezia from the Southern District of Texas handled the civil matter. Assistant U.S. Attorneys John Ross, Jonathan Lee, and Robert Austin Wells from the Eastern District of Texas prosecuted the criminal case.

A copy of the agreement is available at the link below.



Public Affairs Unit

U.S. Attorney’s Office

Southern District of Florida

Updated August 4, 2023

Prescription Drugs
Health Care Fraud